Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
暂无分享,去创建一个
Kerly F. M. Pasqualoto | B. Zingales | C. Franco | Fanny Palace-Berl | Mariana Bury | Adelson Lopes da Silva Neto | João Sussumu Murayama | S. L. Nunes | L. C. Tavares | C. Moraes | Marcelo Silva
[1] B. Zingales. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. , 2017, Acta tropica.
[2] M. Lewis,et al. Putting Infection Dynamics at the Heart of Chagas Disease. , 2016, Trends in parasitology.
[3] Kerly F. M. Pasqualoto,et al. Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients. , 2015, European journal of medicinal chemistry.
[4] M. Miles,et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity , 2014, Memorias do Instituto Oswaldo Cruz.
[5] E. Chatelain,et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development , 2014, Scientific Reports.
[6] Kerly F. M. Pasqualoto,et al. 5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis. , 2013, Bioorganic & medicinal chemistry.
[7] D. Maria,et al. Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents. , 2013, European journal of medicinal chemistry.
[8] A. Rassi,et al. American trypanosomiasis (Chagas disease). , 2012, Infectious disease clinics of North America.
[9] M. Lourenço,et al. Synthesis and Antitubercular Activity of Novel Amino Acid Derivatives , 2012, Chemical biology & drug design.
[10] Kerly F. M. Pasqualoto,et al. Synthesis, molecular modeling and preliminary biological evaluation of a set of 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-oxadiazole as potential antibacterial, anti-Trypanosoma cruzi and antifungal agents. , 2011, Bioorganic & medicinal chemistry.
[11] Kerly F. M. Pasqualoto,et al. Novel benzofuroxan derivatives against multidrug-resistant Staphylococcus aureus strains: design using Topliss' decision tree, synthesis and biological assay. , 2011, Bioorganic & medicinal chemistry.
[12] B. Hall,et al. Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites* , 2011, The Journal of Biological Chemistry.
[13] B. Zingales,et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. , 2010, Memorias do Instituto Oswaldo Cruz.
[14] J. Urbina. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. , 2010, Acta tropica.
[15] J. Coura,et al. Chagas disease: a new worldwide challenge , 2010, Nature.
[16] J. Zock,et al. Applications of High Content Screening in Life Science Research , 2009, Combinatorial chemistry & high throughput screening.
[17] A. Romanha,et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. , 2009, Memorias do Instituto Oswaldo Cruz.
[18] Christine Humblet,et al. GARD: A Generally Applicable Replacement for RMSD , 2009, J. Chem. Inf. Model..
[19] Cun‐Kui Li,et al. Synthesis of Novel 3‐Acetyl‐2‐Aryl‐5‐(3‐Aryl‐1‐Phenyl‐Pyrazol‐4‐yl)‐2,3‐Dihydro‐1,3,4‐Oxadiazoles , 2009 .
[20] D. Horn,et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences of the United States of America.
[21] Márcia M. C. Ferreira,et al. Quimiometria I: calibração multivariada, um tutorial , 1999 .
[22] G. Peluffo,et al. 1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. , 1999, Journal of medicinal chemistry.
[23] Randall D. Tobias,et al. Chemometrics: A Practical Guide , 1998, Technometrics.
[24] A. T. Amaral,et al. Synthesis and biological activity of nifuroxazide and analogs. , 1997, Bollettino chimico farmaceutico.
[25] Shaomeng Wang,et al. Computer Automated log P Calculations Based on an Extended Group Contribution Approach , 1994, J. Chem. Inf. Comput. Sci..
[26] S. G. Andrade,et al. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. , 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[27] G. A. Petersson,et al. A complete basis set model chemistry. II. Open‐shell systems and the total energies of the first‐row atoms , 1991 .
[28] C. Breneman,et al. Determining atom‐centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis , 1990 .
[29] Arup K. Ghose,et al. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..
[30] A. Becke,et al. Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.
[31] Parr,et al. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.
[32] L. Filardi,et al. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[33] S. Croft. In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. , 1986, Parasitology today.
[34] Eamonn F. Healy,et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .
[35] Norman L. Allinger,et al. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms , 1977 .
[36] A. J. Hopfinger,et al. The Influence of Solvent on the Secondary Structures of Poly(L-alanine) and Poly(L-proline) , 1973 .
[37] J. Pontén,et al. Two established in vitro cell lines from human mesenchymal tumours , 1967, International journal of cancer.
[38] Didier Rognan,et al. The practice of medicinal chemistry , 2015 .
[39] L. M. Lima,et al. Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. , 2013, European journal of medicinal chemistry.
[40] B. Pniewska,et al. Structural Investigations of Nifuroxazide, p-Hydroxy-N'-(5-nitrofurfurylidene)benzhydrazide , 1998 .
[41] P. Mahalanobis. On the generalized distance in statistics , 1936 .